|
|
||||||||
|
FJ
EXPRESS SUMMARY ARTICLE The Full-length version of this article is also available, published online March 20, 2001 as doi:10.1096/fj.00-0529fje. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
B signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells1
Colon Cancer Genetics Group, University of Edinburgh Department of Oncology, Division of Clinical and Molecular Medicine and MRC Human Genetics Unit, Western General Hospital, Edinburgh, Scotland
2Correspondence: Colon Cancer Genetics Group, MRC Human Genetics Unit, Western General Hospital, Crewe Rd., Edinburgh EH4 2XU, U.K. E-mail: Lesley.Stark{at}hgu.mrc.ac.uk
SPECIFIC AIM
The aim of this study was to determine whether aspirin mediates an
anti-tumor effect by modulation of NF-
B signaling.
PRINCIPAL FINDINGS
1. Aspirin induces cell death by an active apoptotic process
A dose-dependent reduction in cell viability was observed in SW480
colorectal cancer cells treated with aspirin in the dose range 010 mM
for 24 h or 02 mM aspirin for 48 h. These doses are
comparable to salicylate levels we measured in serum (0.051.13 mM)
from human subjects given a short analgesic dose (600 mg qid) of
aspirin. The reduction in cell viability was accompanied by an increase
in cell death due to apoptosis, as determined by quantitation of cells
showing phosphatidylserine externalization and cell morphology.
Treatment in the presence of cycloheximide showed that aspirin-induced
(10 mM) cell by death required de novo protein synthesis, confirming
that death occurred through an active process, not passive necrosis.
2. Aspirin induces apoptosis in association with
degradation of I
B
and nuclear translocation of
NF-
B
Next, we examined the involvement of the NF-
B signaling pathway
in the apoptotic response of SW480 cells to aspirin. Experiments were
performed in the absence of tumor necrosis factor (TNF) or other
stimulating cytokines, as it is under these experimental conditions
that aspirin induced apoptosis. We found that prolonged treatment with
aspirin (0.52 mM for 48 h or 320 mM for 24 h) induced a
dose-dependent reduction in cytoplasmic I
B
levels that correlated
with the reduction in the number of viable cells. Levels of control
protein (Cu/ZnSOD) were unaffected by aspirin. Mutation of I
B
at
the critical S32/36 phosphorylation sites
(I
BS32/36-tag) and preincubation of cells with
the MG132 proteasome inhibitor blocked aspirin-induced reduction in
I
B
levels. These results indicate that aspirin mediates
phosphorylation and subsequent proteosome-mediated degradation of
I
B
and suggest that this degradation is associated with
aspirin-induced cell death.
Electrophoretic mobility shift assays (EMSAs) revealed that
aspirin-induced I
B
degradation was accompanied by a
dose-dependent specific increase in nuclear NF-
B (p50/p65) DNA
binding complexes (Fig. 1A
, B
). The findings from EMSAs were
further corroborated by immunocytochemistry. Before aspirin treatment,
p65 was localized mainly in the cytoplasm, but after 24 h
treatment with 10 mM aspirin, there was extensive nuclear staining for
the protein (Fig. 1D
). These results establish that 24 h exposure to aspirin activates the NF-
B pathway colorectal cancer
cells.
|
3. Aspirin-induced I
B
degradation and NF-
B nuclear
translocation precede cell death
To investigate the possibility that NF-
B nuclear
translocation was a consequence of cell death, we studied the kinetics
of the aspirin effects on NF-
B signaling and apoptosis. Aspirin (10
mM) treatment induced complete degradation of I
B
after 25 h.
Similarly, an increase in nuclear NF-
B DNA binding was observed
2 h after treatment and persisted for > 16 h. In
comparison, aspirin-induced apoptosis, determined by externalization of
phosphatidylserine, was not detected until 16 h after treatment.
These results show that apoptosis occurred after NF-
B nuclear
translocation, suggesting the possibility of causal relationship
between aspirin-induced NF-
B activation and subsequent cell
death.
4. Inhibition of NF-
B nuclear translocation inhibits
aspirin-induced apoptosis
To definitively prove the relationship between NF-
B nuclear
translocation and aspirin-mediated growth inhibition, we generated
stable transfectants of HRT18 and CT26 colon cancer cells that
constitutively express the I
BS32/36-tag
construct. Using Western blot analysis with the anti-tag antibody, two
HRT18 (I
BS32/36h1, h28) and two CT26
(I
BS32/36ct3, ct4) clones were identified that
expressed high levels of mutant protein. Expression of
I
B
S32/36 resulted in substantial inhibition
of aspirin-induced nuclear translocation of NF-
B in all clones
compared with respective parental cells (Fig. 2A
).If nuclear translocation of NF-
B were contributing to apoptosis,
then inhibition should protect against aspirin-induced cell
death. Indeed, the number of I
BS32/36
expressing viable cells actually increased in the presence of 1 mM
aspirin compared with a 32.4% and 55.8% reduction in viable cell
counts in parental HRT18 and CT26 cells, respectively (Fig 2B
). Similarly, 5 mM aspirin had significantly
(P<0.05) less effect on the viability of mutant I
B
expressing clones than on the viability of parental lines (Fig. 2B
). These data indicate that aspirin-induced apoptosis of
colorectal cancer cells requires phosphorylation and degradation of
I
B
and subsequent nuclear translocation of NF-
B complexes.
|
5. Cell specificity of aspirin-induced I
B
degradation and
apoptosis
Epidemiological studies indicate that nonsteroidal
anti-inflammatory drug (NSAID) -mediated protection is relatively
specific to colorectal tumors. Therefore, we wanted to determine
whether cells that are not derived from colorectal tumors also
responded to aspirin with similar effects on the NF-
B pathway and
cell viability. In all 4 (SW480, HRT-18, HCT116, CT26) colorectal
cancer cell lines tested, 5 mM aspirin induced substantial I
B
degradation whereas 10 mM aspirin induced almost complete degradation.
In contrast, 10 mM aspirin had no effect on I
B
in embryonic
kidney (293) or in lung adenocarcinoma (A549) cells. Substantial growth
inhibitory effects were observed in all colorectal cancer cell lines
treated with 5 or 10 mM aspirin. Numbers of viable cells decreased by
2- to 6.7-fold after aspirin (5 mM) treatment. On the contrary, numbers
of viable 293 cells increased in the presence of 5 mM aspirin while
A549 cells only showed a 1.2-fold decrease in viability after
treatment. These results suggest that aspirin-mediated I
B
degradation and apoptosis may be cell type specific.
6. Aspirin induces I
B
degradation in normal colonic mucosa
and tumors from rectal cancer patients
To establish the potential clinical significance of our results,
we investigated aspirin effects in clinical material. We treated biopsy
samples of normal mucosa and tumor material from patients undergoing
surgical resection for rectal cancer. I
B
degradation was observed
in both the tumor and, to a lesser extent, in the normal mucosa, after
5 h treatment ex vivo with 10 and 20 mM aspirin. No change was
observed in levels of control (Cu/ZnSOD) protein. These data confirm
that clinical tumor biopsy material show the same I
B
response as
observed in cell line experiments.
CONCLUSIONS
There is compelling evidence that NSAIDs have a protective effect against colorectal cancer. However, their detrimental side effects limit their potential use as chemopreventative agents. Therefore, there is a pressing need to understand the mechanisms by which NSAIDs exert their chemopreventative effects in order to allow development of safer alternatives.
We show here for the first time that aspirin mediates a reduction in
cytoplasmic I
B
levels in colorectal cancer cells that is time and
concentration dependent and due to phosphorylation and
proteasome-mediated degradation of the protein. Using EMSAs and
immunocytochemistry, we demonstrate that I
B
degradation results
in nuclear translocation of p50/p65 NF-
B complexes, confirming that
aspirin stimulates the NF-
B pathway. Although these data would
appear to question studies showing that NSAIDs inhibit activation of
NF-
B through specific modulation of the I
B
kinase, previous
studies examined only the very short-term effects of NSAIDs on
activation of NF-
B mediated by cytokines. We investigated the
effects of aspirin alone on NF-
B signaling, which is highly relevant
to the anti-tumor activity of the agent.
The evidence of a link between NF-
B translocation and apoptosis due
to aspirin treatment, was initially implied by the correlation between
I
B
degradation and reduced cell viability. Time course
experiments indicated that the NF-
B response preceded cell death,
raising the possibility of a causal relationship. This was confirmed in
cells we engineered to continuously express a dominant negative mutant
I
B
(I
B
S32/36). These cells showed inhibition of
both aspirin-induced NF-
B nuclear translocation and apoptosis vs.
their parental counterparts. We also considered whether the lack of
apoptotic response to aspirin in the mutant I
B
-expressing clones
might be due to their slower rate of growth compared with parental
cells. However, this is unlikely since these cells grew at a similar
rate to other colorectal cancer cell lines (SW480) in which aspirin
induced substantial apoptosis. Thus, we conclude that it is NF-
B
nuclear translocation that mediates aspirin-induced apoptosis of
colorectal cancer cells.
These novel findings of a prolonged effect of aspirin on NF-
B
signaling provide new insight into the mechanism of action of aspirin
against colorectal cancer and will inform chemoprevention
strategies.
|
FOOTNOTES
1 To read the full text of this article, go to http://www.fasebj.org/cgi/doi/10.1096/fj.00-0529fje ; to cite this
article, use FASEB J. (March 20, 2001) 10.1096/fj.00-0529fje ![]()
This article has been cited by other articles:
![]() |
L. A. Stark, K. Reid, O. J. Sansom, F. V. Din, S. Guichard, I. Mayer, D. I. Jodrell, A. R. Clarke, and M. G. Dunlop Aspirin activates the NF-{kappa}B signalling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer Carcinogenesis, May 1, 2007; 28(5): 968 - 976. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Thoms, M. G. Dunlop, and L. A. Stark p38-Mediated Inactivation of Cyclin D1/Cyclin-Dependent Kinase 4 Stimulates Nucleolar Translocation of RelA and Apoptosis in Colorectal Cancer Cells Cancer Res., February 15, 2007; 67(4): 1660 - 1669. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Borthwick, A. S. Johnson, M. Partington, J. Burn, R. Wilson, and H. M. Arthur Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism FASEB J, October 1, 2006; 20(12): 2009 - 2016. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Dikshit, M. Chatterjee, A. Goswami, A. Mishra, and N. R. Jana Aspirin Induces Apoptosis through the Inhibition of Proteasome Function J. Biol. Chem., September 29, 2006; 281(39): 29228 - 29235. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Battaglia, M. Salvi, and A. Toninello Oxidative Stress Is Responsible for Mitochondrial Permeability Transition Induction by Salicylate in Liver Mitochondria J. Biol. Chem., October 7, 2005; 280(40): 33864 - 33872. [Abstract] [Full Text] [PDF] |
||||
![]() |
C R Boland, M G Luciani, C Gasche, and A Goel INFECTION, INFLAMMATION, AND GASTROINTESTINAL CANCER Gut, September 1, 2005; 54(9): 1321 - 1331. [Full Text] [PDF] |
||||
![]() |
L. A. Stark and M. G. Dunlop Nucleolar Sequestration of RelA (p65) Regulates NF-{kappa}B-Driven Transcription and Apoptosis Mol. Cell. Biol., July 15, 2005; 25(14): 5985 - 6004. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Kim, H.-J. Jeong, I.-Y. Choi, K.-M. Lee, R.-K. Park, S.-H. Hong, and H.-M. Kim Cyclooxygenase-2 Inhibitor SC-236 [4-[5-(4-Chlorophenyl)-3-(trifluoromethyl)-1-pyrazol-1-l] Benzenesulfonamide] Suppresses Nuclear Factor-{kappa}B Activation and Phosphorylation of p38 Mitogen-Activated Protein Kinase, Extracellular Signal-Regulated Kinase, and c-Jun N-Terminal Kinase in Human Mast Cell Line Cells J. Pharmacol. Exp. Ther., July 1, 2005; 314(1): 27 - 34. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. H. Hardwick, M. van Santen, G. R. van den Brink, S. J. H. van Deventer, and M. P. Peppelenbosch DNA array analysis of the effects of aspirin on colon cancer cells: involvement of Rac1 Carcinogenesis, July 1, 2004; 25(7): 1293 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Williams, N. Nath, J. Chen, T. R. Hundley, J. Gao, L. Kopelovich, K. Kashfi, and B. Rigas Growth Inhibition of Human Colon Cancer Cells by Nitric Oxide (NO)-Donating Aspirin Is Associated with Cyclooxygenase-2 Induction and {beta}-Catenin/T-Cell Factor Signaling, Nuclear Factor-{kappa}B, and NO Synthase 2 Inhibition: Implications for Chemoprevention Cancer Res., November 15, 2003; 63(22): 7613 - 7618. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ricchi, A. D. Palma, T. D. Matola, A. Apicella, R. Fortunato, R. Zarrilli, and A. M. Acquaviva Aspirin Protects Caco-2 Cells from Apoptosis after Serum Deprivation through the Activation of a Phosphatidylinositol 3-Kinase/AKT/p21Cip/WAF1Pathway Mol. Pharmacol., August 1, 2003; 64(2): 407 - 414. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dihlmann, S. Klein, and M. v. K. Doeberitz Reduction of {beta}-Catenin/T-Cell Transcription Factor Signaling by Aspirin and Indomethacin Is Caused by an Increased Stabilization of Phosphorylated {beta}-Catenin Mol. Cancer Ther., June 1, 2003; 2(6): 509 - 516. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Rajakangas, S. Basu, I. Salminen, and M. Mutanen Adenoma Growth Stimulation by the trans-10, cis-12 Isomer of Conjugated Linoleic Acid (CLA) Is Associated with Changes in Mucosal NF-{kappa}B and Cyclin D1 Protein Levels in the Min Mouse J. Nutr., June 1, 2003; 133(6): 1943 - 1948. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Goel, D. K. Chang, L. Ricciardiello, C. Gasche, and C. R. Boland A Novel Mechanism for Aspirin-mediated Growth Inhibition of Human Colon Cancer Cells Clin. Cancer Res., January 1, 2003; 9(1): 383 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. J. Sansom, L. A. Stark, M. G. Dunlop, and A. R. Clarke Suppression of Intestinal and Mammary Neoplasia by Lifetime Administration of Aspirin in ApcMin/+ and ApcMin/+, Msh2-/- Mice Cancer Res., October 1, 2001; 61(19): 7060 - 7064. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. TEGEDER, J. PFEILSCHIFTER, and G. GEISSLINGER Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J, October 1, 2001; 15(12): 2057 - 2072. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |